Clinical Trial Update: GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

This update describes a Phase II multicenter study evaluating pirtobrutinib, rituximab, and venetoclax in patients with previously untreated mantle cell lymphom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Pirtobrutinib (pirtobrutinib)
• Rituxan (rituximab)
• Venclexta (venetoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Mantle Cell Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING